Abstract:ABSTRACT Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at high risk of infection with SARS-CoV-2 and hospitalization. In addition, monoclonal antibody therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped neutralization. In this context, there is interest in understanding the clinical benefit associated with COVID-19 convalescent plasma collected from persons who have been both naturally infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 (“vax-plasma”). Thus, we report the clinical outcome of 386 immunocompromised outpatients who were diagnosed with COVID-19 and who received contemporary COVID-19-specific therapeutics (standard-of-care group) and a subgroup who also received concomitant treatment with very high titer COVID-19 convalescent plasma (vax-plasma group) with a specific focus on hospitalization rates. The overall hospitalization rate was 2.2% (5 of 225 patients) in the vax-plasma group and 6.2% (10 of 161 patients) in the standard-of-care group, which corresponded to a relative risk reduction of 65% ( P = 0.046). Evidence of efficacy in nonvaccinated patients cannot be inferred from these data because 94% (361 of 386 patients) of patients were vaccinated. In vaccinated patients with immunosuppression and COVID-19, the addition of vax-plasma or very high titer COVID-19 convalescent plasma to COVID-19-specific therapies reduced the risk of disease progression leading to hospitalization. IMPORTANCE As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386 immunocompromised outpatients who were treated with COVID-19-specific therapeutics and a subgroup also treated with vaccine-boosted convalescent plasma. We found that the administration of vaccine-boosted convalescent plasma was associated with a significantly decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients.

Antibody response and intra‐host viral evolution after plasma therapy in COVID‐19 patients pre‐exposed or not to B‐cell‐depleting agents

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

COVID-19-neutralizing antibodies predict disease severity and survival

Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID‐19

SARS-CoV-2 evolution during treatment of chronic infection

Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report

Spike and nucleocapsid antibody dynamics following SARS‐CoV‐2 infection and vaccination: Implications for sourcing COVID‐19 convalescent plasma from routinely collected blood donations

Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?

Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma

Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment

Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response

Convalescent plasma therapy - a silver lining for COVID-19 management?

Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era

Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience

Convalescent plasma transfusion for immunocompromised viremic patients with COVID‐19: A retrospective multicenter study